Background: Bladder carcinoma is the second most common cause of death among all genitourinary tumors. Tumor recurrence, multifocality and metastasis are main causes of related mortality The primary objective of the present study is to evaluate the expression of Sp1 and Par3 in urinary bladder carcinoma and to investigate their correlation with clinicopathological characteristics and patient survival Patients and Methods: This prospective cohort study included 50 urothelial carcinoma cases investigated for immunohistochemical expressions of Sp1 and Par3 followed them for five years or until death. The expression of markers in all tissue samples was assessed, analyzed, and correlated with clinical-pathological parameters and outcomes. Results: The high expression of Sp1, and low expression of Par3 was significantly associated with poor clinicopathological characteristics and unfavourable overall survival. Conclusion: The results suggested that Sp1 and Par3 may have roles in modulation of tumor invasion. Sp1 and Par3 may serve as valuable prognostic markers or therapeutic targets for urothelial carcinoma.
No takes yet. Share an insight, caveat, or question.
Fouad et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: